The Impact of Dexamethasone Administration on Labor Progression in Pregnant Women: A Randomized, Double-Blind Clinical Trial.

Q2 Medicine
Medical Journal of the Islamic Republic of Iran Pub Date : 2025-03-24 eCollection Date: 2025-01-01 DOI:10.47176/mjiri.39.45
Sonia Ranjbar, Fariba Seyedoshohadaei, Nasrin Soufizadeh, Roya Mardani, Maryam Afraie, Sara Chavoshinezhad, Zeinab Hemati
{"title":"The Impact of Dexamethasone Administration on Labor Progression in Pregnant Women: A Randomized, Double-Blind Clinical Trial.","authors":"Sonia Ranjbar, Fariba Seyedoshohadaei, Nasrin Soufizadeh, Roya Mardani, Maryam Afraie, Sara Chavoshinezhad, Zeinab Hemati","doi":"10.47176/mjiri.39.45","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The role of dexamethasone in labor progression during the latent and active phases has been widely debated. This study aimed to evaluate the effects of dexamethasone on labor progression, delivery outcomes, and neonatal health.</p><p><strong>Methods: </strong>This multicenter, randomized controlled trial included 4 groups of pregnant individuals: (1) the first group-intervention in the active phase receiving dexamethasone; (2) the second group-intervention in the latent phase receiving dexamethasone; (3) the third group-control in the active phase; and (4) the fourth group-control in the latent phase. Participants were randomly assigned to each group. The primary outcomes were time from the latent phase to the active phase, duration of active labor, cervical dilation rate, and time from intervention to delivery. Secondary outcomes included cesarean section rate, adverse events (vaginal bleeding, fetal heart rate [FHR)] decelerations), and neonatal outcomes (Appearance, Pulse, Grimace, Activity and Respiration [APGAR] scores and neonatal intensive care unit [NICU] admissions). Statistical analyses included 1-way analysis of variance for normally distributed variables, the Kruskal-Wallis test for non-normally distributed variables, chi-square and Fisher exact tests for categorical data, and Bonferroni correction for multiple comparisons.</p><p><strong>Results: </strong>A total of 120 participants were enrolled, with 75 in each group. The first group had the shortest time from the latent to active phase (4.85 hours, 95% CI: 4.32-5.38) and the shortest duration of active labor (1.91 hours, 95% CI: 1.52-2.30), compared to the other groups (<i>P</i> < 0.001). Cervical dilation rate was also highest in the first group (2.57 cm/hour, 95% CI: 2.13-3.01), significantly faster than in other groups (<i>P</i> < 0.001). The first group demonstrated the shortest time from intervention to delivery compared with the second and third groups (7.21 hours, 95% CI: 6.31-8.11), significantly shorter than the second (9.32 hours, 95% CI: 8.23-10.41) and third groups (9.05 hours, 95% CI: 8.15-9.95) (<i>P</i> < 0.001). There were no significant differences in cesarean section rates despite the differences in labor times and progression (5% overall, <i>P</i> = 0.320), with the second group having the lowest rate (0%) and the first group the lowest among interventions (3.33%). Adverse events, including vaginal bleeding and FHR decelerations, were rare and did not show significant differences. Neonatal APGAR scores were high across all groups (1 minute: 9, 95% CI: 8.8-9.2; 5 minutes: 10, 95% CI: 9.9-10), with no significant differences between groups.</p><p><strong>Conclusion: </strong>Dexamethasone administration during the active phase of labor significantly shortened the time from the latent phase to active labor, reduced the duration of active labor, and enhanced cervical dilation rate, without adversely affecting neonatal health or increasing adverse events. Further studies are needed to confirm these findings and assess the long-term effects on both maternal and neonatal outcomes.</p>","PeriodicalId":18361,"journal":{"name":"Medical Journal of the Islamic Republic of Iran","volume":"39 ","pages":"45"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309336/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Journal of the Islamic Republic of Iran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47176/mjiri.39.45","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The role of dexamethasone in labor progression during the latent and active phases has been widely debated. This study aimed to evaluate the effects of dexamethasone on labor progression, delivery outcomes, and neonatal health.

Methods: This multicenter, randomized controlled trial included 4 groups of pregnant individuals: (1) the first group-intervention in the active phase receiving dexamethasone; (2) the second group-intervention in the latent phase receiving dexamethasone; (3) the third group-control in the active phase; and (4) the fourth group-control in the latent phase. Participants were randomly assigned to each group. The primary outcomes were time from the latent phase to the active phase, duration of active labor, cervical dilation rate, and time from intervention to delivery. Secondary outcomes included cesarean section rate, adverse events (vaginal bleeding, fetal heart rate [FHR)] decelerations), and neonatal outcomes (Appearance, Pulse, Grimace, Activity and Respiration [APGAR] scores and neonatal intensive care unit [NICU] admissions). Statistical analyses included 1-way analysis of variance for normally distributed variables, the Kruskal-Wallis test for non-normally distributed variables, chi-square and Fisher exact tests for categorical data, and Bonferroni correction for multiple comparisons.

Results: A total of 120 participants were enrolled, with 75 in each group. The first group had the shortest time from the latent to active phase (4.85 hours, 95% CI: 4.32-5.38) and the shortest duration of active labor (1.91 hours, 95% CI: 1.52-2.30), compared to the other groups (P < 0.001). Cervical dilation rate was also highest in the first group (2.57 cm/hour, 95% CI: 2.13-3.01), significantly faster than in other groups (P < 0.001). The first group demonstrated the shortest time from intervention to delivery compared with the second and third groups (7.21 hours, 95% CI: 6.31-8.11), significantly shorter than the second (9.32 hours, 95% CI: 8.23-10.41) and third groups (9.05 hours, 95% CI: 8.15-9.95) (P < 0.001). There were no significant differences in cesarean section rates despite the differences in labor times and progression (5% overall, P = 0.320), with the second group having the lowest rate (0%) and the first group the lowest among interventions (3.33%). Adverse events, including vaginal bleeding and FHR decelerations, were rare and did not show significant differences. Neonatal APGAR scores were high across all groups (1 minute: 9, 95% CI: 8.8-9.2; 5 minutes: 10, 95% CI: 9.9-10), with no significant differences between groups.

Conclusion: Dexamethasone administration during the active phase of labor significantly shortened the time from the latent phase to active labor, reduced the duration of active labor, and enhanced cervical dilation rate, without adversely affecting neonatal health or increasing adverse events. Further studies are needed to confirm these findings and assess the long-term effects on both maternal and neonatal outcomes.

地塞米松给药对孕妇产程的影响:一项随机双盲临床试验
背景:地塞米松在潜伏期和活跃期产程中的作用一直存在广泛的争论。本研究旨在评估地塞米松对产程、分娩结局和新生儿健康的影响。方法:本多中心随机对照试验纳入4组孕妇:(1)第一组在妊娠活动性期接受地塞米松干预;(2)第二组在潜伏期接受地塞米松干预;(3)主动阶段的第三组控制;(4)潜伏期第四组对照。参与者被随机分配到每一组。主要观察指标为潜伏期至活跃期时间、活跃期产程持续时间、宫颈扩张率、干预至分娩时间。次要结局包括剖宫产率、不良事件(阴道出血、胎心率[FHR]减慢)和新生儿结局(外貌、脉搏、鬼脸、活动和呼吸[APGAR]评分和新生儿重症监护病房[NICU]入院情况)。统计分析包括正态分布变量的单向方差分析,非正态分布变量的Kruskal-Wallis检验,分类数据的卡方检验和Fisher精确检验,多重比较的Bonferroni校正。结果:共入组120例,每组75例。与其他两组相比,第一组潜伏期至活跃期时间最短(4.85 h, 95% CI: 4.32 ~ 5.38),活跃期持续时间最短(1.91 h, 95% CI: 1.52 ~ 2.30) (P < 0.001)。第一组宫颈扩张率最高(2.57 cm/h, 95% CI: 2.13 ~ 3.01),明显快于其他各组(P < 0.001)。与第二组和第三组相比,第一组从干预到分娩的时间最短(7.21小时,95% CI: 6.31-8.11),显著短于第二组(9.32小时,95% CI: 8.23-10.41)和第三组(9.05小时,95% CI: 8.15-9.95) (P < 0.001)。两组间剖宫产率差异无统计学意义(5%,P = 0.320),其中第二组最低(0%),第一组最低(3.33%)。不良事件,包括阴道出血和FHR减速,是罕见的,没有显着差异。所有组新生儿APGAR评分均较高(1分钟:9,95% CI: 8.8-9.2;5分钟:10,95% CI: 9.9-10),组间无显著差异。结论:在产程活跃期给予地塞米松可显著缩短潜伏期至产程活跃期的时间,缩短产程持续时间,提高宫颈扩张率,对新生儿健康无不良影响,未增加不良事件。需要进一步的研究来证实这些发现,并评估对孕产妇和新生儿结局的长期影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
90
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信